Abstract
Comprehensive molecular testing is essential to provide personalized and effective care for patients with metastatic non-squamous (non-Sq) NSCLC. Ordering of next-generation gene sequencing (NGS) is often delayed until the first medical oncology visit. To improve rates of timely comprehensive molecular profiling among newly diagnosed patients with advanced non-Sq NSCLC, we implemented a reflex, molecular testing pathway (NGS and RNA fusion panel) on tumor, nodal or metastatic specimens, initiated at the time of initial pathology review, that obviated the need for a separate specimen-specific order.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
